1. Efficacy and Safety of a Diet Enriched with EPA and DHA, Turmeric Extract and Hydrolysed Collagen in Management of Naturally Occurring Osteoarthritis in Cats: A Prospective, Randomised, Blinded, Placebo- and Time-Controlled Study.
- Author
-
Lefort-Holguin, Manuela, Delsart, Aliénor, Otis, Colombe, Moreau, Maxim, Barbeau-Grégoire, Maude, Mellet, Florence, Biourge, Vincent, Lussier, Bertrand, Pelletier, Jean-Pierre, Martel-Pelletier, Johanne, and Troncy, Eric
- Abstract
Simple Summary: Feline osteoarthritis (OA) is a painful degenerative musculoskeletal disease characterised by functional alterations and degraded animal welfare. As OA cannot be cured, veterinarians' therapeutic goal is to reduce pain symptoms to better the animal's quality of life. The pharmacological arsenal is reduced in cats because of the specific therapeutic margin and the occurrence of side effects. Non-pharmacological avenues such as nutraceuticals are promising. However, there is a need for strong, evidence-based research on the effects of nutraceuticals in feline OA. The present study evaluated the efficacy and safety of a therapeutic diet containing omega-3s, hydrolysed collagen and turmeric extract with a clinical metrology instrument and three objective outcomes that were all previously validated as specific, sensitive and reliable. The diet was proven to provide a clear treatment effect in all cats, including those who were moderately and severely affected, to yield a high rate of compliance to administration and to be devoid of any side effect, which is of fundamental importance when treating chronic illnesses like OA. This study evaluated a therapeutic diet high in eicosapentaenoic (EPA) and docosahexaenoic acid (DHA) of marine source (EPA:DHA ratio 0.69:1), turmeric extract, and hydrolysed collagen in cats (N = 30) with naturally occurring osteoarthritis (OA) over a 13-week (W) period, followed by a 4-W washout, using four previously validated pain/functional outcomes. Compared to the placebo diet, the therapeutic diet significantly improved peak vertical force (p = 0.017; W16, 64% responders), correlating to enhanced weight bearing; stair assay compliance (p < 0.001; W16, 87% responders), reflecting reduced fatigue related to OA pain; night-time actimetry (cohort effect; p = 0.05, 67% responders), suggesting greater spontaneous mobility and comfort; and MI-CAT(V) score (cohort effect; p < 0.001, 80% responders), indicating reduced functional impairments. The earliest therapeutic response was observed at W06, marked by an inflection point between actimetric linear regressions of both cohorts, confirmed by significant MI-CAT(V) differences (p < 0.007; W08; W12; W16). The MI-CAT(V) clinical metrology instrument was validated for inter-rater reliability, minimal placebo effect (<15% responders), and OA severity clustering. Despite baseline differences in biomechanical assessments (p < 0.05), both moderate and severe OA clusters responded equally positively to the therapeutic diet. Based on all outcomes, the therapeutic diet showed promise for the long-term management of feline OA, with no observed side effects. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF